FAROTTI, LUCIA
 Distribuzione geografica
Continente #
NA - Nord America 734
EU - Europa 348
AS - Asia 271
Totale 1.353
Nazione #
US - Stati Uniti d'America 734
IE - Irlanda 140
SG - Singapore 96
IT - Italia 77
VN - Vietnam 75
HK - Hong Kong 47
CN - Cina 40
RO - Romania 23
RU - Federazione Russa 23
FI - Finlandia 14
UA - Ucraina 14
FR - Francia 13
DE - Germania 10
SE - Svezia 9
BE - Belgio 5
GB - Regno Unito 5
JP - Giappone 4
KR - Corea 4
CZ - Repubblica Ceca 3
PL - Polonia 3
CH - Svizzera 2
ES - Italia 2
NL - Olanda 2
TR - Turchia 2
AL - Albania 1
IN - India 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
RS - Serbia 1
Totale 1.353
Città #
Chandler 210
Dublin 140
Singapore 78
Dong Ket 75
San Mateo 51
Hong Kong 47
Altamura 37
Boardman 32
Santa Clara 32
Wilmington 32
Medford 29
Princeton 28
Des Moines 27
Lawrence 27
Perugia 23
Ann Arbor 22
Timisoara 18
Beijing 17
Andover 14
Los Angeles 12
Falls Church 10
Saint Petersburg 10
Dallas 7
Norwalk 7
Brussels 5
Bucharest 5
San Paolo di Civitate 5
Helsinki 4
Lappeenranta 4
Redwood City 4
Seoul 4
Paris 3
Den Haag 2
Donostia / San Sebastian 2
Fairfield 2
Fremont 2
Izmir 2
New York 2
Recanati 2
Tokyo 2
Almaty 1
Alviano 1
Atlanta 1
Bologna 1
Colombo 1
Denver 1
Edinburgh 1
Falkenstein 1
Houston 1
Kiev 1
Linyi 1
Ludwigshafen 1
Luxembourg 1
Mejiro 1
Milan 1
Moscow 1
Nis 1
Olomouc 1
Queens 1
Radeberg 1
Redmond 1
Rome 1
San Severo 1
Shantou 1
Tirana 1
Washington 1
Zhengzhou 1
Totale 1.062
Nome #
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease 83
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis 75
Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI) 74
Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology 73
Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 64
Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms 58
Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study 57
Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers 54
Biomarker-based signature of alzheimer’s disease in pre-MCI individuals 53
Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases 51
Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine 50
Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers 49
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes 48
Two-year longitudinal monitoring of amnestic mild cognitive impairment patients with prodromal Alzheimer's disease using topographical biomarkers derived from functional magnetic resonance imaging and electroencephalographic activity 45
White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers 44
Parkinson's and Lewy body dementia CSF biomarkers 43
Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study 42
Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms 42
Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study 41
Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker 41
Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics 41
Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: A 'European ADNI study' 40
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders 39
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease 38
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. 37
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry 37
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study 36
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores 35
Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores 16
null 13
Totale 1.419
Categoria #
all - tutte 7.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.142


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202049 0 0 0 0 0 1 11 3 11 10 13 0
2020/2021186 2 1 7 6 64 2 5 4 1 4 2 88
2021/2022223 4 38 0 2 11 8 7 58 8 17 35 35
2022/2023596 33 110 7 71 40 75 0 30 202 2 19 7
2023/2024169 14 21 9 7 2 0 42 3 4 15 31 21
2024/2025172 4 39 11 28 46 44 0 0 0 0 0 0
Totale 1.419